Cost-effectiveness of clopidogrel plus aspirin vs. aspirin alone for secondary-prevention of cardiovascular events: Results from the CHARISMA trial

被引：0
|
作者：
Chen, Jersey
Bhatt, Deepak L.
Schneider, Elizabeth
Shi, Chunxue
Caro, Jaime
Proskorovsky, Irina
Hacke, Werner
Fox, Keith A.
Cohen, David J.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Harvard Clin Res Inst, Boston, MA USA
[4] Caro Res, Concord, MA USA
[5] Univ Heidelberg, D-6900 Heidelberg, Germany
[6] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland
来源：
CIRCULATION | 2006年 / 114卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：826 / 826
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN CHINESE PATIENTS WITH DIABETES
    Jiang, M.
    Li, P.
    Zheng, X.
    Deng, J.
    Zhao, M.
    Fang, Y.
    VALUE IN HEALTH, 2019, 22 : S129 - S129
  • [22] Aspirin plus clopidogrel vs aspirin alone for preventing cardiovascular events among patients at high risk for cardiovascular events (vol 320, pg 593, 2018)
    Donadini, M. P.
    Bellesini, M.
    Squizzato, A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (12): : 1288 - 1288
  • [23] Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1561): : 196 - 197
  • [24] COST-EFFECTIVENESS ANALYSIS OF PLUS ASPIRIN VS PLACEBO PLUS ASPIRIN IN THE TREATMENT OF ISCHEMIC STROKE BASED ON A RANDOMIZED CLINICAL TRIAL
    Xiang, Y.
    Fan, W.
    Zhou, L.
    Guo, Z.
    Zhou, N.
    Yang, N.
    Hu, M.
    VALUE IN HEALTH, 2020, 23 : S93 - S93
  • [25] Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: Subgroup analysis of the CHARISMA randomized trial
    Hart, Robert G.
    Bhatt, Deepak L.
    Hacke, Werner
    Fox, Keith A. A.
    Hankey, Graeme J.
    Berger, Peter B.
    Hu, Tingfei
    Topol, Eric J.
    CEREBROVASCULAR DISEASES, 2008, 25 (04) : 344 - 347
  • [26] Cost-Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable
    Coleman, Craig I.
    Straznitskas, Andrew D.
    Sobieraj, Diana M.
    Kluger, Jeffrey
    Anglade, Moise W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (07): : 1020 - 1025
  • [27] Cost-Effectiveness of Clopidogrel-Aspirin Versus Aspirin Alone for Acute Transient Ischemic Attack and Minor Stroke
    Pan, Yuesong
    Wang, Anxin
    Liu, Gaifen
    Zhao, Xingquan
    Meng, Xia
    Zhao, Kun
    Liu, Liping
    Wang, Chunxue
    Johnston, S. Claiborne
    Wang, Yilong
    Wang, Yongjun
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (03):
  • [28] Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis
    Shah, H
    Gondek, K
    CLINICAL THERAPEUTICS, 2000, 22 (03) : 362 - 370
  • [29] A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: Clopidogrel plus aspirin versus aspirin alone
    Schleinitz, MD
    Heidenreich, PA
    ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) : 251 - 259
  • [30] An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients
    Annemans, L
    Gabriel, S
    Speisser, J
    Vranckx, K
    De Knock, M
    Carita, P
    VALUE IN HEALTH, 2003, 6 (06) : 621 - 622
12345